Topical steroid

EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)

Retrieved on: 
Monday, July 19, 2021

Now available: Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age orolderintroduces useof PAD Technology.

Key Points: 
  • Now available: Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age orolderintroduces useof PAD Technology.
  • "Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment ofplaque psoriasis, with proven efficacy, safety and tolerability.
  • Wynzora Cream is based on PADTechnology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in aconvenient-to-use aqueous formulation.
  • Wynzora (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis inadults.It is notknown ifWynzoraCream is safeand effectivein children.

LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Friday, April 23, 2021

LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.

Key Points: 
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.
  • For more information please visit www.LEO-Pharma.com\nBieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis.
  • Tralokinumab for moderate\xe2\x80\x90to\xe2\x80\x90severe atopic dermatitis: results from two 52\xe2\x80\x90week, randomized, double\xe2\x80\x90blind, multicentre, placebo\xe2\x80\x90controlled phase III trials (ECZTRA 1 and ECZTRA 2).
  • Tralokinumab plus topical corticosteroids for the treatment of moderate\xe2\x80\x90to\xe2\x80\x90severe atopic dermatitis: results from the double\xe2\x80\x90blind, randomized, multicentre, placebo\xe2\x80\x90controlled phase III ECZTRA 3 trial.

Nuvothera's Prosoria Launches Improved Psoriasis Treatment System

Retrieved on: 
Tuesday, February 2, 2021

FORT WORTH, Texas, Feb. 2, 2021 /PRNewswire/ --Nuvothera, a Fort Worth, Texas-based biotech company, has launched an improved version of its revolutionary Prosoria psoriasis treatment system for this tough-to-treat skin condition.

Key Points: 
  • FORT WORTH, Texas, Feb. 2, 2021 /PRNewswire/ --Nuvothera, a Fort Worth, Texas-based biotech company, has launched an improved version of its revolutionary Prosoria psoriasis treatment system for this tough-to-treat skin condition.
  • The new stream-lined, 2-step treatment is simpler than the original 3-step system and now includes a treatment gel and an exfoliating and moisturizing cream.
  • If you seek treatment from a dermatologist, you are likely to receive a topical steroid for milder psoriasis.
  • Nuvothera's products include Prosoria, a topical daily psoriasis treatment system, and our Nuvothera Super-Micronized Turmeric Curcumin dietary supplement.

Insights on the Netherton Syndrome Global Market (2020 to 2027) - by Epidemiology, Therapy and Geography

Retrieved on: 
Wednesday, November 11, 2020

The report highlights trends prevailing in the global Netherton syndrome market, and the drivers and hindrances pertaining to the market growth.

Key Points: 
  • The report highlights trends prevailing in the global Netherton syndrome market, and the drivers and hindrances pertaining to the market growth.
  • Based on therapy, the global Netherton syndrome market is segmented into keratolytic agents, oral and topical steroids and retinoids, topical calcineurin inhibitors, biological therapies, and radiation therapies.
  • In 2019, the keratolytic agents segment held the largest share of the global Netherton syndrome market.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Netherton syndrome market.

LEO Pharma announces U.S. Food and Drug Administration (FDA) acceptance of Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis

Retrieved on: 
Thursday, July 9, 2020

The acceptance of the BLA is the beginning of the formal review procedure for this potential new treatment by the FDA.

Key Points: 
  • The acceptance of the BLA is the beginning of the formal review procedure for this potential new treatment by the FDA.
  • There is a significant unmet medical need for people whose moderate-to-severe atopic dermatitis remains uncontrolled, said Kim Kjller, M.D., Executive Vice President, Global Research and Development, LEO Pharma.
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.
  • Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no.

LEO Pharma Announces European Medicines Agency Acceptance of Marketing Authorization Application for tralokinumab for the Treatment of Adults With Moderate-To-Severe Atopic Dermatitis

Retrieved on: 
Thursday, June 11, 2020

LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for tralokinumab, an investigational product for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for tralokinumab, an investigational product for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD).
  • People living with atopic dermatitis often face tremendous physical, social and emotional challenges, said Kim Kjller, M.D., Executive Vice President, Global Research and Development, LEO Pharma.
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.
  • Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no.

LEO Pharma Presents Phase 3 Data in Atopic Dermatitis and Plaque Psoriasis at the American Academy of Dermatology Virtual Meeting Experience 2020

Retrieved on: 
Tuesday, June 2, 2020

Tralokinumab is a fully human monoclonal antibody that specifically neutralizes the IL-13 cytokine,1,2 a key driver of the underlying chronic inflammation in atopic dermatitis (AD).

Key Points: 
  • Tralokinumab is a fully human monoclonal antibody that specifically neutralizes the IL-13 cytokine,1,2 a key driver of the underlying chronic inflammation in atopic dermatitis (AD).
  • Effects on Endocrine System: Can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of treatment.
  • Allergic Contact Dermatitis: Allergic contact dermatitis has been observed with topical calcipotriene and topical corticosteroids.
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.

Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05%

Retrieved on: 
Monday, October 14, 2019

LAKE FOREST, Ill., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc.(Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for betamethasone dipropionate lotion USP (augmented), 0.05%.

Key Points: 
  • LAKE FOREST, Ill., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc.(Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for betamethasone dipropionate lotion USP (augmented), 0.05%.
  • The product is manufactured at Akorns Amityville, New York manufacturing facility.
  • According to IQVIA, U.S. sales of betamethasone dipropionate lotion (augmented), 0.05% were approximately $10 million for the twelve months ended August 2019.
  • Betamethasone dipropionate lotion (augmented) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older.

Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults

Retrieved on: 
Tuesday, June 25, 2019

Patients used DUOBRII once daily for eight weeks and were re-evaluated every four weeks after for a year.

Key Points: 
  • Patients used DUOBRII once daily for eight weeks and were re-evaluated every four weeks after for a year.
  • DUOBRII Lotion is for use on the skin only; do not use it in your mouth, eyes, or vagina.
  • Stop using DUOBRII Lotion and tell your healthcare provider right away if you become pregnant while using DUOBRII Lotion.
  • Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.

FDA Approves Bausch Health's DUOBRII™ (Halobetasol Propionate And Tazarotene) Lotion 0.01%/0.045% For Plaque Psoriasis In Adults

Retrieved on: 
Thursday, April 25, 2019

DUOBRII Lotion is priced at $825 for a supply of a 100-gram tube, which is more than 50 percent lower than other branded topical combination products.

Key Points: 
  • DUOBRII Lotion is priced at $825 for a supply of a 100-gram tube, which is more than 50 percent lower than other branded topical combination products.
  • DUOBRII Lotion is for use on the skin only; do not use it in your mouth, eyes, or vagina.
  • Stop using DUOBRII Lotion and tell your healthcare provider right away if you become pregnant while using DUOBRII Lotion.
  • Long-term safety results from a phase 3 open-label study of a fixed combinationhalobetasol propionate 0.01% andtazarotene0.045% lotion in moderate-to-severe plaque psoriasis.